Studies have reported that ovarian cancer patients with BRCA1/2 gene mutations are sensitive to platinum-based chemotherapeutics and poly ADP-Ribose Polymerase (PARP) inhibitors [11–14]. The gene discussed is BRCA1; the disease is ovarian cancer.